WILVER PETER M
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Raises Shoals Technologies Price Target to $11. Barclays maintained an Overweight rating on Shoals Technologies Group and raised its price target to $11. This move supports the stock's position within a broader sector analysis, where Oppenheimer highlighted top power technology stocks amid rising costs. The new target aligns closely with the current average analyst estimate of $11.22, reflecting continued institutional interest in the company's power technology solutions.
Transaction History
| LIVN | ▲ Buy | Option Exercise | 4,042 | $0 | 6/15/2026 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 486 | $39K | 6/15/2026 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 410 | $19K | 6/15/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 3,416 | $0 | 6/15/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 2,680 | $0 | 6/15/2024 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 585 | $31K | 6/15/2024 | View on chart |
| BAX | ▲ Buy | Grant | 5,952 | $0 | 5/7/2024 | View on chart |
| SHLS | ▲ Buy | Grant | 20,619 | $0 | 5/2/2024 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 2,082 | $0 | 6/15/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 445 | $22K | 6/15/2023 | View on chart |
| SHLS | ▲ Buy | Grant | 8,325 | $0 | 5/4/2023 | View on chart |
| BAX | ▲ Buy | Grant | 4,573 | $0 | 5/2/2023 | View on chart |
| BAX | ▲ Buy | Grant | 2,481 | $0 | 5/10/2022 | View on chart |
| SHLS | ▲ Buy | Grant | 12,935 | $0 | 5/5/2022 | View on chart |
| SHLS | ▲ Buy | Grant | 2,539 | $0 | 8/19/2021 | View on chart |
| SHLS | ▲ Buy | Grant | 5,078 | $0 | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.